Marc Casper, CEO of Thermo Fisher Scientific, is the highest-paid healthcare CEO per the Wall Street Journal’s annual ranking of S&P 500 companies.
WSJ’s analysis found that median CEO pay rose to nearly $18 million at S&P 500 companies in 2025 — a new high.
392 total CEOs are in the annual ranking. Twenty-three of these CEOs are from the “pharmaceuticals, biotechnology, and life sciences” industries. Their rankings are below:
14. Marc Casper, Thermo Fisher Scientific, $80 million
38. David Ricks, Eli Lily, $37 million
55. Joaquin Duato, Johnson & Johnson, $33 million
57. Robert Michael, Abbvie, $33 million
78. Daniel O’Day, Gilead Sciences, $28 million
80. Ari Bousbib, Iqvia Holdings, $28 million
83. Albert Bouria, Pfizer, $28 million
106. Robert Bradway, Amgen, $25 million
116. Rainer Blair, Danaher, $24 million
117. Christopher Viehbacher, Biogen, $24 million
142. Christopher Boerner, Bristol Myers Squibb, $22 million
153. Reshma Kewalramani, Vertex Pharmaceuticals, $21 million
156. Robert Davis, Merck, $21 million
164. Stephane Bancel, Moderna, $20 million
179. Kristen Peck, Zoetis, $19 million
248. James Foster, Charles River Laboratories International, $15 million
252. Scott Smith, Viatris, $15 million
283. Udit Bahtra, Waters, $14 million
288. Prahlad Singh, Revvity, $14 million
299. Padraig McDonnell, Agilent Technologies, $13 million
369. Leonard Schleifer, Regeneron Pharmaceuticals, $7.3 million
370. Eric Green, West Pharmaceutical Services, $7.2 million
372. Patrick Kaltenbach, Mettler Toledo, $6.7 million
